Bayforest Capital’s Immunome IMNM Stock Holding History

Bayforest Capital’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,271	Closed	-$115K	–	1072
2026 Q1	$115K	Buy	+5,271	New	+$117K	0.13%	310

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Bayforest Capital's IMNM Position: Q2 2026 in Review

Bayforest Capital sold out of Immunome (IMNM) in Q2 2026, closing a stake of 5,271 shares — an estimated $115K sold.

Bayforest Capital first reported a position in IMNM in Q1 2026 and held it in 1 quarter. The position peaked at $115K in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Bayforest Capital reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
Bayforest Capital sold 5,271 Immunome shares in Q2 2026, an estimated $115K.
Bayforest Capital first reported a position in Immunome in Q1 2026 and held it in 1 quarter.
Bayforest Capital's Immunome position peaked at $115K in Q1 2026.
203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.